【Editor's Choice | Preview of Selected Companies at BIO Asia-Taiwan】
EirGenix's Development Capacity Extends to CDMO and Biosimilars Across the US, Europe, and Taiwan.
 
EirGenix (6589.TWO) is one of the few companies in Asia that possesses both mammalian cell and microbial cell systems. Additionally, EirGenix has a complete downstream protein purification system for producing drugs for clinical trials, as well as expansion of production facilities for commercial manufacturing.
 
Through its expertise in development and manufacturing, as well as its vertical integration operating model, EirGenix can provide high-quality and cost-effective services and biologics in response to the increasing prices of biopharmaceutical drugs worldwide, thus reduce medical expenses for patients and governments.
 
To learn more about EirGenix, please visit GlobalBio's:
https://lnkd.in/gaTjfCMN
 
#EirGenix #CDMO #biosimilars #biologics #biopharmaceutical